The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases.
Microbiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches.